KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Leases (2020 - 2025)

Historic Operating Leases for Adaptive Biotechnologies (ADPT) over the last 6 years, with Q3 2025 value amounting to $72.4 million.

  • Adaptive Biotechnologies' Operating Leases fell 1154.34% to $72.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year decrease of 1154.34%. This contributed to the annual value of $79.1 million for FY2024, which is 1145.57% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Operating Leases of $72.4 million as of Q3 2025, which was down 1154.34% from $74.4 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Operating Leases' 5-year high stood at $108.0 million during Q3 2021, with a 5-year trough of $72.4 million in Q3 2025.
  • Moreover, its 5-year median value for Operating Leases was $94.2 million (2023), whereas its average is $92.0 million.
  • In the last 5 years, Adaptive Biotechnologies' Operating Leases soared by 16064.3% in 2021 and then crashed by 1203.91% in 2025.
  • Adaptive Biotechnologies' Operating Leases (Quarter) stood at $106.7 million in 2021, then fell by 7.42% to $98.8 million in 2022, then fell by 9.5% to $89.4 million in 2023, then fell by 11.46% to $79.1 million in 2024, then decreased by 8.58% to $72.4 million in 2025.
  • Its Operating Leases stands at $72.4 million for Q3 2025, versus $74.4 million for Q2 2025 and $76.4 million for Q1 2025.